Cyclooxygenase-2 in oncogenesis

Clinica Chimica Acta

Volumn 412, Issue 9-10, 2011, Pages 671-687

  Rizzo, Maria Teresa ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase 2; Mechanisms; Prostaglandin E2; Signaling pathways; Tumors

Indexed keywords

ACETYLSALICYLIC ACID; AROMATASE INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DIMETHYLCELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SULINDAC; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLON CANCER; COX 2 GENE; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; GENE; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; INTRADUCTAL CARCINOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; STOMACH ULCER; TRANSCRIPTION REGULATION; TRANSLATION REGULATION; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR PROMOTION; TUMOR VASCULARIZATION;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 79951727359     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.12.026     Document Type: Review

References (274)

1. Otto J.C., Smith W.L. Prostaglandin endoperoxide synthases -1 and -2. J Lipid Mediat Cell Signal 1995, 12:139-156.
2. Jarvin R., Jarvin I., Kurg R., Brash A.R., Samel N. On the evolutionary origin of cyclooxygenase (COX) enzymes: characterization of marine invertebrate COX genes points to independent duplication events in vertebrate and invertebrate lineages. J Biol Chem 2004, 279:13624-13633.
3. Dey I., Keller K., Beley A., Chadee K. Identification and characterization of a cyclo-oxygenase-like enzyme from Entamoeba histolytica. Proc Natl Acad Sci USA 2003, 100:13561-13566.
4. Hassid A., Levine L. Induction of fatty acid cyclo-oxygenase activity in canine kidney cells (MDCK) by benzo (a) pyrene. J Biol Chem 1977, 252:6591-6593.
5. Pong S.S., Hong S.L., Levine L. Prostaglandin production by methylcholanthrene-transformed mouse BALB/3T3. Requirement for protein synthesis. J Biol Chem 1977, 252:1408-1433.
6. Ohichi K., Levine L. Stimulation of prostaglandin synthesis by tumor-promoting phorbol-12, 1-diesters in canine kidney (MDCK) cells. Cycloheximide inhibits the stimulated prostaglandin synthesis, deacylation of lipids, and morphological changes. J Biol Chem 1978, 253:4783-4790.
7. Xie W.L., Chipman J.G., Robertson D.L., Erikson R.L., Simmons D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991, 88:2692-2696.
8. Kujubu D.A., Fletcher B.S., Varnum B.C., Lim R.W., Herschman H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991, 266:12866-12872.
9. Fletcher B.S., Kujubu D.A., Perrin D.M., Herschman H.R. Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem 1992, 267:4338-4344.
10. Hla T., Neilson K. human cycloxygenase-1 cDNA. Proc Natl Acad Sci USA 1992, 89:7384-7388.
11. Ristimaki A., Garfinkel S., Wessendorf J., Maciag T., Hla T. T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 1994, 269:11769-11775.
12. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993, 268:9049-9054.
13. Seibert K., Zhang Y., Leahy K., et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994, 91:12013-12017.
14. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
15. Kaufmann W.E., Worley P.F., Pegg J., Bremer M., Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996, 93:2317-2321.
16. Harris R.C., McKanna J.A., Akai Y., Jacobson H.R., Dubois R.N., Breyer M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994, 94:2504-2510.
17. Dinchuk J.E., Car B.D., Focht R.J., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 1995, 378:406-409.
18. Bogar L.J., Bartula L.L., Parkman H.P., Myers S.I. Enhanced bradykinin-stimulated prostaglandin release in the acutely inflamed guinea pig gallbladder is due to new synthesis of cyclooxygenase-1 and prostacyclin synthase. J Surg Res 1999, 84:71-76.
19. Ueda N., Yamashita R., Yamamoto S., Ishimura K. Induction of cyclooxygenase-1 in a human megakaryoblastic cell line (CMK) differentiated by phorbol ester. Biochim Biophys Acta 1997, 1344:103-110.
20. Langenbach R., Loftin C., Lee C., Tiano H. Cyclooxygenase knockout mice: models for elucidating isoform-specific functions. Biochem Pharmacol 1999, 58:1237-1246.
21. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., DuBois R.N. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-1188.
22. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999, 59:198-204.
23. Tucker O.N., Dannenberg A.J., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999, 59:987-990.
24. Goulet A.C., Einsphar J.G., Alberts D.S., et al. Analysis of cyclo-oxygenase-2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003, 2:713-718.
25. Shono T., Tofilon P.J., Bruner J.M., Owolabi O., Lang F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 2001, 61:4375-4381.
26. Hida T., Yatabe Y., Achiwa H., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998, 58:3761-3764.
27. Bernard M.P., Bancos S., Sime P.J., Phipps R.P. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Curr Pharm Des 2008, 14:2051-2060.
28. Tazawa R., Xu X.M., Wu K.K., Wang L.H. Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochem Biophys Res Commun 1994, 203:190-199.
29. Appleby S.B., Ristimaki A., Neilson K., Narko K., Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994, 302:723-727.
30. Roos K.L.T., Simmons D.L. Cyclooxygenase variants: the role of alternative splicing. Biochem Biophys Res Commun 2005, 338:62-69.
31. Bi N., Yang M., Zhang L., et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:2383-2390.
32. Kraemer S.A., Meade E.A., DeWitt D.L. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5'-flanking regulatory sequences. Arch Biochem Biophys 1992, 293:391-400.
33. Chen C.Y., Shyu A.B. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995, 20:465-470.
34. Garavito R.M., Malkowski M.G., DeWitt D.L. The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat 2002, 68-69:129-152.
35. Luong C., Miller A., Barnett J., Chow J., Ramesha C., Browner M.F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2. Nat Struct Biol 1996, 3:927-933.
36. Mbonye U.R., Wada M., Rieke C.J., Tang H.-Y., Dewitt D.L., Smith W.L. The 19-amino acid cassette of cyclooxygenase-2 mediates entry of the protein into the endoplasmic reticulum-associated degradation system. J Biol Chem 2006, 281:35770-35778.
37. Otto J.C., DeWitt D.L., Smith W.L. N-glycosylation of prostaglandin endoperoxide synthases-1 and -2 and their orientations in the endoplasmic reticulum. J Biol Chem 1993, 268:18234-18242.
38. Sevigny M.B., Li C.-F., Alas M., Hughes-Fulford M. Glycosylation regulates turnover of cyclooxygenase-2. FEBS Lett 2006, 580:6533-6536.
39. Kim S.F., Huri D.A., Snyder S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310:1966-1970.
40. Morita I., Schindler M., Regier M.K., et al. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem 1995, 270:10902-10908.
41. Wang D., Wang H., Shi Q., et al. Prostaglandin E2 promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 2004, 6:285-295.
42. Liou J.-Y., Aleksic N., Chen S.-F., Han T.-J., Shyue S.-K., Wu K.K. Mitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance. Exp Cell Res 2005, 306:75-84.
43. Accioly M.T., Pacheco P., Maya-Monteiro C.M., et al. Lipid bodies are reservoirs of cyclooxygenase-2 and sites of prostaglandin-E2 synthesis in colon cancer cells. Cancer Res 2008, 68:1732-1740.
44. Needleman P., Turk J., Jakschik B.A., Morrison A.R., Lefkowith J.B. Arachidonic acid metabolism. Annu Rev Biochem 1986, 55:69-102.
45. Marnett L.J. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999, 424:83-95.
46. Rouzer C.A., Marnett L.J. Non-redundant functions of cyclooxygenases: oxygenation of endocannabinoids. J Biol Chem 2008, 283:8065-8069.
47. Lecomte M., Laneuville O., Ji C., DeWitt D.L., Smith W.L. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994, 269:13207-13215.
48. Schneider C., Boeglin W.E., Yin H., Stec D.F., Voehler M. Convergent oxygenation of arachidonic acid by 5-lipoxygenase and cyclooxygenase-2. J Am Chem Soc 2006, 128:720-721.
49. Wiese F.W., Thompson P.A., Kadlubar F.F. Carcinogen substrate specificity of human COX-1 and COX-2. Carcinogenesis 2001, 22:5-10.
50. Kirschenbaum A., Liotta D.R., Yao S., et al. Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. J Clin Endocrinol Metab 2000, 85:3436-3441.
51. Chen C.C., Sun Y.T., Chen J.J., Chiu K.T. TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway. J Immunol 2000, 165:2719-2728.
52. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996, 97:2672-2679.
53. Chan A.T., Giovannucci E.L., Meyerhardt J.A., Schernhammer E.S., Curhan G.C., Fuchs C.S. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005, 294:914-923.
54. Salinas C.A., Kwon E.M., Fitzferald L.M., et al. Use of aspirin and other nonsteroidal antiinflammatoy medications in relation to prostate cancer risk. Am J Epidemiol 2010, 172:578-590.
55. Khuder S.A., Mutgi A.B. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001, 84:1188-1192.
56. Chang E.T., Zheng T., Weir E.G., et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 2004, 96:305-315.
57. Giardiello F.M., Offerhaus J.A., Tersmette A.C., et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996, 38:578-581.
58. Steinbach G., Lynch P.M., Phillips R.K.S., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000, 342:1946-1952.
59. Goss K.H., Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000, 18:1967-1979.
60. Chan A.T., Ogino S., Fuchs C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302:649-658.
61. Holmes M.D., Chen W.Y., Li L., Hertzmark E., Spiegelman D., Hankinson S.E. Aspirin intake and survival after breast cancer. J Clin Oncol 2010, 28:1467-1472.
62. Richardsen E., Uglehus R.D., Due J., Busch C., Busund L.-T. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol 2010, 34:316-322.
63. Mrena J., Wiksten J.-P., Kokkola A., Nordling S., Ristimaki A., Haglund C. COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumour Biol 2010, 31:1-7.
64. Mascaux C., Martin B., Paesmans M., et al. Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer 2006, 95:139-145.
65. Denkert C., Winzer K.-J., Muller B.-M., et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003, 97:2978-2987.
66. Kim J.H., Bossuyt V., Ponn T., Lannin D., Haffty B.G. Cyclooxygenase-2 expression in postmastectomy chest wall relapse. Clin Cancer Res 2005, 11:5199-5205.
67. Bos P.D., Zhang X.H.F., Nadal C., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
68. Visscher D.W., Pankratz V.S., Santisteban M., et al. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 2008, 100:421-427.
69. Denkert C., Kobel M., Pest S., et al. Expression of cyclo-oxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002, 160:893-903.
70. Kim G.E., Kim Y.B., Cho N.H., et al. Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival. Clin Cancer Res 2004, 10:1366-1374.
71. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005, 1755:135-150.
72. Cervello M., Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006, 12:5113-5121.
73. Castelao J.E., Bart R.D., DiPerna C.A., Sievers E.M., Bremner R.M. Lung cancer and cyclooxygenase-2. Ann Thorac Surg 2003, 76:1327-1335.
74. Chan G., Boyle J.O., Yang E.K., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999, 59:991-994.
75. Lee H.M., Baek S.K., Kwon S.Y., et al. Cyclooxygenase-1 and -2 expressions in the human thyroid gland. Eur Arch Otorhinolaryngol 2006, 263:199-204.
76. Vincent C., Donnard M., Bordessoule D., Turlure P., Trimoreau F., Denizot Y. Cyclooxygenase-2 (Cox-2) and blast cells of patients with acute leukemia. Leuk Res 2008, 32:671-673.
77. Giles F.J., Kantarjian H.M., Bekele B.N., et al. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 2002, 119:38-45.
78. Ohsawa M., Fukushima H., Ikura Y., et al. Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma 2006, 47:1863-1871.
79. Paydas S., Ergin M., Erdogan S., Seydaoglu G. Cyclooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma 2007, 48:389-395.
80. Cetin M., Buyukberber S., Demir M., et al. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol 2005, 80:169-173.
81. Ryan E.P., Pollock S.J., Kaur K., et al. Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. Clin Immunol 2006, 120:76-90.
82. Sheng H., Shao J., Washington M.K., DuBois R.N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001, 276:18075-18081.
83. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58:362-366.
84. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
85. Tsujii M., DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83:493-501.
86. Tsujii M., Kawano S., DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336-3340.
87. Sharma S., Zhu L., Yang S.C., et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 2005, 175:813-819.
88. Lee S.H., Williams M.V., Dubois R.N., Blair I.A. Cyclooxygenase-2-mediated DNA damage. J Biol Chem 2005, 280:28337-28346.
89. Yano T., Zissel G., Muller-Qernheim J., Shin S.J., Satoh H., Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 2002, 518:154-158.
90. Lau L.M., Wolter J.K., Lau J.T., et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 2009, 28:2024-2033.
91. Greenhough A., Smartt H.J.M., Moore A.E., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
92. Sato N., Maehara N., Goggins M. Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res 2004, 64:6950-6956.
93. Nakao S., Kuwano T., Tsutsumi-Miyahara C., et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest 2005, 115:2979-2991.
94. Katoh H., Hosono K., Ito Y., et al. COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems. Am J Pathol 2010, 176:1469-1483.
95. Hu M., Peluffo G., Chen H., Gelman R., Schnitt S., Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci USA 2009, 106:3372-3377.
96. Sharma S., Stolina M., Yang S.-C., et al. Tumor cyclo-oxygenase-2-dependent suppression of dendritic cell function. Clin Cancer Res 2003, 9:961-968.
97. Sharma S., Yang S.-C., Zhu L., et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005, 65:5211-5220.
98. Araki Y., Okamura S., Hussain S.P., et al. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003, 63:728-734.
99. Kawaguchi H., Pilbeam C.C., Gronowicz G., et al. Transcriptional induction of prostaglandin G/H synthase-2 by basic fibroblast growth factor. J Clin Invest 1995, 96:923-930.
100. Shigemasa K., Tian X., Gu L., Shiroyama Y., Nagai N., Ohama K. Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas. Int J Oncol 2003, 22:99-105.
101. Fordyce C., Fessenden T., Pickering C., et al. DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions. Cancer Prev Res 2010, 3:190-201.
102. Daneau G., Boidot R., Martinive P., Feron O. Identification of cyclooxygenase-2 as a major actor of the transcriptomic adaptation of endothelial and tumor cells to cyclic hypoxia: effect on angiogenesis and metastases. Clin Cancer Res 2010, 16:410-419.
103. Choy H., Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance?. J Natl Cancer Inst 2003, 95:1440-1452.
104. Ferrandina G., Lauriola L., Distefano M.G., et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002, 973-998.
105. Bakhle Y.S., Botting R.M. Cyclooxygenase-2 and its regulation in inflammation. Mediat Inflamm 1996, 5:305-323.
106. Schlosser W., Schlosser S., Ramadani M., Gansauge F., Gansauge S., Beger H.-G. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 2002, 25:26-30.
107. Ling F.C., Baldus S.E., Khochfar J., et al. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer. Histopathology 2007, 50:203-209.
108. Hendel J., Nielsen O.H. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol 1997, 2:1170-1173.
109. Clevers H. At the crossroads of inflammation and cancer. Cell 2004, 118:671-674.
110. Liu C.H., Chang S.H., Narko K., et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001, 276:18563-18569.
111. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
112. Chulada P.C., Thompson M.B., Mahler J.F., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60:4705-4708.
113. Oshima M., Dinchuk J.E., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
114. Crawford Y.G., Gauthier M.L., Joubel A., et al. Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 2004, 5:263-273.
115. Colby J.K., Klein R.D., McArthur M.J., et al. Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia (New York) 2008, 10:782-796.
116. Oyama K., Fujimura T., Ninomiya I., et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasia-adenocarcinoma sequence in rats. Carcinogenesis 2005, 26:565-570.
117. Miwa K., Segawa M., Takano Y., et al. Induction of oesophageal and forestomach carcinomas in rats by reflux of duodenal contents. Br J Cancer 1994, 70:185-189.
118. Zhang F., Altorki N.K., Wu Y.C., Soslow R.A., Subbaramaiah K., Dannenberg A.J. Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 2001, 121:1391-1399.
119. Morris C.D., Armstrong G.R., Bigley G., Green H., Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96:990-996.
120. Sun W.-H., Yu Q., Shen H., et al. Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol 2004, 10:2809-2813.
121. Sung J.J., Leung W.K., Go M.Y., et al. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am J Pathol 2000, 157:729-735.
122. Konturek P.C., Konturek S.J., Pierzchalski P., et al. Gastric MALT-lymphoma, gastrin and cyclooxygenases. Acta Gastroenterol Belg 2002, 65:17-23.
123. Toller I.M., Hitzler I., Sayi A., Mueller A. Prostaglandin E2 prevents Helicobacter-induced gastric preneoplasia and facilitates persistent infection in a mouse model. Gastroenterology 2010, 138:1455-1467.
124. Muller-Decker K., Neufang G., Berger I., Neumann M., Marks F., Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci USA 2002, 99:12483-124838.
125. Rundhaug J.E., Pavone A., Kim E., Fischer S.M. The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent. Mol Carcinog 2007, 46:981-992.
126. Al-Salihi M.A., Terrece Pearman A., Doan T., et al. Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. Cancer Lett 2009, 273:225-232.
127. Kohno H., Suzuki R., Sugie S., Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005, 5:46.
128. Ishikawa T., Herschman H.R. Tumor formation in a mouse model of colitis- associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010, 31:729-736.
129. Sano H., Kawahito Y., Wilder R.L., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 35:3785-3789.
130. Hiraga T., Myoui A., Choi M.E., Yoshikawa H., Yoneda T. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res 2006, 66:2067-2073.
131. Kundu N., Fulton A.M. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 2002, 62:2343-2346.
132. Kozaki K., Koshikawa K., Tatematsu Y., et al. Multi-faceted analyses of a highly metastatic human lung cancer cell line NCI-H460-LNM35 suggest mimicry of inflammatory cells in metastasis. Oncogene 2001, 20:4228-4234.
133. Duque J., Fresno M., Iniguez M.A. Expression and function of the nuclear factor of activated T cells in colon carcinoma cells: involvement in the regulation of cyclooxygenase-2. J Biol Chem 2005, 280:8686-8693.
134. Solinas G., Marchesi F., Garlanda C., Mantovani A., Allavena P. Inflammation-mediated promotion of invasion and metastasis. Cancer Metastasis Rev 2010, 29:243-248.
135. Neil J.R., Johnson K.M., Nemenoff R.A., Schiemann W.P. Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 2008, 29:2227-2235.
136. Chang Y.-W.E., Marlin J.W., Chance T.W., Jakobi R. RhoA mediates cyclooxygenase-2 signaling to disrupt the formation of adherens junctions and increase cell motility. Cancer Res 2006, 66:11700-11708.
137. Dohadwala M., Yang S.-C., Luo J., et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res 2006, 66:5338-5345.
138. Lara-Pezzi E., Gomez-Gaviro M.V., Galvez B.G., et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002, 110:1831-1838.
139. Attiga F.A., Fernandez P.M., Weeraratna A.T., Manyak M.J., Patierno S.R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000, 60:4629-4637.
140. Sivula A., Talvensaari-Mattila A., Lundin J., et al. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005, 89:215-220.
141. Zeng Q., McCauley L.K., Wang C.-Y. Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem 2002, 277:50137-50142.
142. Pan M.-R., Hou M.-F., Chang H.-C., Hung W.-C. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem 2008, 283:11155-11163.
143. Kakiuchi Y., Tsuji S., Tsujii M., et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002, 62:1567-1572.
144. Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999, 94:451-455.
145. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
146. Deng W.-G., Zhu Y., Wu K.K. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004, 103:2135-2142.
147. Sheng H., Williams C.S., Shao J., Liang P., DuBois R.N., Beauchamp R.D. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998, 273:22120-22127.
148. Subbaramaiah K., Altorki N., Chung W.J., Mestre J.R., Sampat A., Dannenberg A.J. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999, 274:10911-10915.
149. Csiki I., Yanagisawa K., Haruki N., et al. Thioredoxin-1 modulates transcription of cyclooxygenase-2 via hypoxia-inducible factor-1alpha in non-small cell lung cancer. Cancer Res 2006, 66:143-150.
150. Sharma-Walia N., Paul A.G., Bottero V., et al. Kaposi's sarcoma associated herpes virus (KSHV) induced COX-2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion. PLoS Pathog 2010, 6:e1000777.
151. Zhuang Z.-H., Tsao S.-W., Deng W., et al. Early upregulation of cyclooxygenase-2 in human papillomavirus type 16 and telomerase-induced immortalization of human esophageal epithelial cells. J Gastroenterol Hepatol 2008, 23:1613-1620.
152. Jones M.K., Sasaki E., Halter F., et al. HGF triggers activation of the COX-2 gene in rat gastric epithelial cells: action mediated through the ERK2 signaling pathway. FASEB J 1999, 13:2186-2194.
153. Tsatsanis C., Androulidaki A., Venihaki M., Margioris A.N. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006, 38:1654-1661.
154. Subbaramaiah K., Telang N., Ramonetti J.T., et al. Transcription of Cyclooxygenase-2 Is Enhanced in Transformed Mammary Epithelial Cells. Cancer Res 1996, 56:4424-4429.
155. Xie W., Fletcher B.S., Andersen R.D., Herschman H.R. v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element. Mol Cell Biol 1994, 14:6531-6539.
156. Kim S.-H., Oh J.-M., No J.-H., Bang Y.-J., Juhnn Y.-S., Song Y.-S. Involvement of NF-kappa B and AP-1 in COX-2 upregulation by human papillomavirus 16 E5 oncoprotein. Carcinogenesis 2009, 30:753-757.
157. Yiu G.K., Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 2006, 281:12210-12217.
158. Subbaramaiah K., Norton L., Gerald W., Dannenberg A.J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002, 277:18649-18657.
159. Yang F., Bleich D. Transcriptional regulation of cyclooxygenase-2 gene in pancreatic beta-cells. J Biol Chem 2004, 279:35403-35411.
160. Martey C.A., Baglole C.J., Gasiewicz T.A., Sime P.J., Phipps R.P. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2005, 289:L391-L399.
161. Kraemer S.A., Arthur K.A., Denison M.S., Smith W.L., DeWitt D.L. Regulation of prostaglandin endoperoxide H synthase-2 expression by 2, 3, 7, 8,-tetrachlorodibenzo-p-dioxin. Arch Biochem Biophys 1996, 330:319-328.
162. Kaidi A., Qualtrough D., Williams A.C., Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 2006, 66:6683-6691.
163. Hinz B., Brune K., Pahl A. Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs. Biochem Biophys Res Commun 2000, 278:790-796.
164. Howe L.R., Subbaramaiah K., Chung W.J., Dannenberg A.J., Brown A.M. Transcriptional activation of cyclooxygenase-2 in Wnt-1-transformed mouse mammary epithelial cells. Cancer Res 1999, 59:1572-1577.
165. Morin P.J., Sparks A.B., Korinek, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
166. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170.
167. Razin A., Riggs A.D. DNA methylation and gene function. Science 1980, 210:604-610.
168. Momparler R.L., Bovenzi V. DNA methylation and cancer. J Cell Physiol 2000, 183:145-154.
169. Song S.H., Jong H.S., Choi H.H., et al. Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. Cancer Res 2001, 61:4628-4635.
170. Akhtar M., Cheng Y., Magno R.M., et al. Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res 2001, 61:2399-2403.
171. Ristimaki A., Narko K., Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J 1996, 318:325-331.
172. Dixon D.A., Kaplan C.D., McIntyre T.M., Zimmerman G.A., Prescott S.M. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. J Biol Chem 2000, 275:11750-11757.
173. Cok S.J., Morrison A.R. The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001, 276:23179-23185.
174. Ma W.J., Cheng S., Campbell C., Wright A., Furneaux H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 1996, 271:8144-8151.
175. Dixon D.A., Tolley N.D., King P.H., et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 2001, 108:1657-1665.
176. Denkert C., Weichert W., Pest S., et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004, 64:189-195.
177. Lim S.-J., Kim H.J., Kim J.Y., Park K., Lee C.-M. Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 2007, 26:229-234.
178. Lee H.K., Jeong S. Beta-catenin stabilizes cyclooxygenase-2 mRNA by interacting with AU-rich elements of 3'-UTR. Nucleic Acids Res 2006, 34:5705-5714.
179. Matsumura T., Suzuki T., Aizawa K., et al. Regulation of transforming growth factor-beta-dependent cyclooxygenase-2 expression in fibroblasts. J Biol Chem 2009, 284:35861-35871.
180. Dixon D.A., Balch G.C., Kedersha N., et al. Regulation of cyclooxygenase-2 expression by the translational silencer TIA-1. J Exp Med 2003, 198:475-481.
181. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010, 79:351-379.
182. Iorio M.V., Croce C.M. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27:5848-5856.
183. Chakrabarty A., Tranguch S., Daikoku T., Jensen K., Furneaux H., Dey S.K. MicroRNA regulation of cyclooxygenase-2 during embryo implantation. Proc Natl Acad Sci USA 2007, 104:15144-15149.
184. Strillacci A., Griffoni C., Sansone P., et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009, 315:1439-1447.
185. Mbonye U.R., Yuan C., Harris C.E., et al. Two distinct pathways for cyclooxygenase-2 protein degradation. J Biol Chem 2008, 283:8611-8623.
186. Wada M., Saunders T.L., Morrow J., et al. Two pathways for cyclooxygenase-2 protein degradation in vivo. J Biol Chem 2009, 284:30742-30753.
187. Chen S.-F., Liou J.-Y., Huang T.-Y., et al. Caveolin-1 facilitates cyclooxygenase-2 protein degradation. J Cell Biochem 2010, 109:356-362.
188. Loh J.-K., Hwang S.-L., Lieu A.-S., Huang T.-Y., Howng S.-L. The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal. J Neurooncol 2002, 57:147-150.
189. Cayeux S.J., Beverley P.C., Schulz R., Dorken B. Elevated plasma prostaglandin E2 levels found in 14 patients undergoing autologous bone marrow or stem cell transplantation. Bone Marrow Transplant 1993, 12:603-608.
190. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993, 122:518-523.
191. Kibbey W.E., Bronn D.G., Minton J.P. Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma. Prostaglandins Med 1979, 2:133-139.
192. Murakami M., Naraba H., Tanioka T., et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem 2000, 275:32783-32792.
193. Backlund M.G., Mann J.R., Holla V.R., et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005, 280:3217-3223.
194. Ding Y., Tong M., Liu S., Moscow J.A., Tai H.-H. NAD+-linked 15-hydroxyprostaglandin dehydrogenase (15-PGDH) behaves as a tumor suppressor in lung cancer. Carcinogenesis 2005, 26:65-72.
195. Payner T., Leaver H.A., Knapp B., et al. Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A. Mol Cancer Ther 2006, 5:1817-1826.
196. Sugimoto Y., Narumiya S. Prostaglandin E receptors. J Biol Chem 2007, 282:11613-11617.
197. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8:289-293.
198. Han C., Michalopoulos G.K., Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006, 207:261-270.
199. Sonoshita M., Takaku K., Sasaki N., et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001, 7:1048-1051.
200. Mutoh M., Watanabe K., Kitamura T., et al. Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 2002, 62:28-32.
201. Kawamori T., Kitamura T., Watanabe K., et al. Prostaglandin E receptor subtype EP1 deficiency inhibits colon cancer development. Carcinogenesis 2005, 26:353-357.
202. Holla V.R., Mann J.R., Shi Q., DuBois R.N. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem 2006, 281:2676-2682.
203. Ghosh M., Ai Y., Narko K., Wang Z., Peters J.M., Hla T. PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat 2009, 88:97-100.
204. Ansari K.M., Rundhaug J.E., Fischer S.M. Multiple signaling pathways are responsible for prostaglandin E2-induced murine keratinocyte proliferation. Mol Cancer Res 2008, 6:1003-1016.
205. Pozzi A., Yan X., Macias-Perez I., et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 2004, 279:29797-29804.
206. Wang D., Buchanan F.G., Wang H., Dey S.K., DuBois R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res 2005, 65:1822-1829.
207. Donnini S., Finetti F., Solito R., et al. EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways. FASEB J 2007, 21:2418-2430.
208. Chang S.-H., Ai Y., Breyer R.M., Lane T.F., Hla T. The Prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res 2005, 65:4496-4499.
209. Shao J., Evers B.M., Sheng H. Prostaglandin E2 synergistically enhances receptor tyrosine kinase-dependent signaling system in colon cancer cells. J Biol Chem 2004, 279:14287-14293.
210. Krysan K., Reckamp K.L., Dalwadi H., et al. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 2005, 65:6275-6281.
211. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005, 310:1504-1510.
212. North T.E., Goessling W., Walkley C.R., et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447:1007-1011.
213. Bidwell P., Joh K., Leaver H.A., Rizzo M.T. Prostaglandin E2 activates cAMP response element-binding protein in glioma cells via a signaling pathway involving PKA-dependent inhibition of ERK. Prostaglandins Other Lipid Mediat 2010, 91:18-29.
214. Kleiveland C.R., Kassem M., Lea T. Human mesenchymal stem cell proliferation is regulated by PGE2 through differential activation of cAMP-dependent protein kinase isoforms. Exp Cell Res 2008, 314:1831-1838.
215. Macias-Perez I.M., Zent R., Carmosino M., et al. Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo. J Biol Chem 2008, 283:12538-12545.
216. Chu J., Lloyd F.L., Trifan O.C., Knapp B., Rizzo M.T. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003, 2:1-7.
217. Dormond O., Foletti A., Paroz C., Ruegg C. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001, 7:1041-1047.
218. Finetti F., Solito R., Morbidelli L., Giachetti A., Ziche M., Donnini S. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 2008, 283:2139-2146.
219. Jain S., Chakraborty G., Raja R., Kale S., Kundu G.C. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008, 68:7750-7759.
220. Amano H., Hayashi I., Endo H., et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003, 197:221-232.
221. Kubo H., Hosono K., Suzuki T., et al. Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomed Pharmacother 2010, 64:101-106.
222. Ogawa Y., Suzuki T., Oikawa A., et al. Bone marrow-derived EP3-expressing stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009, 382:720-725.
223. Buchanan F.G., Wang D., Bargiacchi F., DuBois R.N. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003, 278:35451-35457.
224. Kim J.I., Lakshmikanthan V., Frilot N., Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res 2010, 8:569-577.
225. Dohadwala M., Batra R.K., Luo J., et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002, 277:50828-50833.
226. Yang S.-F., Chen M.-K., Hsieh Y.-S., et al. PGE2/EP1 signaling pathway enhances ICAM-1 expression and cell motility in oral cancer cells. J Biol Chem 2010, 285:29808-29816.
227. Liu J.-F., Fong Y.-C., Chang C.-S., et al. Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 2010, 9:43.
228. Porter B.O., Malek T.R. Prostaglandin E2 inhibits T-cell-activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction. Eur J Immunol 1999, 29:2360-2365.
229. Krysan K., Dalwadi H., Sharma S., Pold M., Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 2004, 64:6359-6362.
230. Tessner T.G., Muhale F., Riehl T.E., Anant S., Stenson W.F. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 2004, 114:1676-1685.
231. Greenhough A., Wallam C.A., Hicks D.J., Moorghen M., Williams A.C., Paraskeva C. The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE2 signalling in colorectal adenoma cells. Oncogene 2010, 29:3398-3410.
232. Goodwin J.S., Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol 1983, 3:295-315.
233. Harizi H., Juzan M., Pitard V., Moreau J.F., Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol 2002, 168:2255-2263.
234. Baxevanis C.N., Reclos G.J., Gritzapis A.D., Dedousis G.V., Missitzis I., Papamichail M. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 1993, 72:491-501.
235. Sharma S., Yang S.C., Zhu L., Reckamp K., et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005, 65:5211-5220.
236. Sinha P., Clements V.K., Fulton A.M., Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 2007, 67:4507-4513.
237. Chemnitz J.M., Driesen J., Classen S., et al. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res 2006, 66:1114-1122.
238. Mukherjee P., Basu G.D., Tinder T.L., et al. Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 2009, 182:216-224.
239. Basu G.D., Tinder T.L., Bradley J.M., et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006, 177:2391-2402.
240. Kurumbail R.G., Stevens A.M., Gierse J.K., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384:644-648.
241. Harris R.E., Alshafie G.A., Abou-Issa H.M., Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclo-oxygenase 2 inhibitor. Cancer Res 2000, 60:2101-2103.
242. Leahy K.M., Ornberg R.L., Wang Y., Zweifel B.S., Koki A.T., Masferrer J.L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002, 62:625-631.
243. Totzke G., Schulze-Osthoff K., Janicke R.U. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 2003, 22:8021-8030.
244. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002, 62:2029-2033.
245. Grosch S., Maier T.J., Schiffmann S., Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98:736-747.
246. Grosch S., Tegeder I., Niederberger E., Brautigam L., Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15:2742-2744.
247. Johnson A.J., Hsu A.L., Lin H.P., Song X., Chen C.S. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002, 366:831-837.
248. Weber A., Casini A., Heine A., et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem 2004, 47:550-557.
249. Ostrowski J., Wocial T., Skurzak H., Bartnik W. Do altering in ornithine decarboxylase activity and gene expression contribute to antiproliferative properties of COX inhibitors?. Br J Cancer 2003, 88:1143-1151.
250. Kardosh A., Wang W., Uddin J., et al. Dimethyl-celecoxib (DMC), a derivative of celecoxib that lacks cyclooxygenase-2-inhibitory function, potently mimics the anti-tumor effects of celecoxib on Burkitt's lymphoma in vitro and in vivo. Cancer Biol Ther 2005, 571-582.
251. Pyrko P., Soriano N., Kardosh A., et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 2006, 18-5:19.
252. Wobst I., Schiffmann S., Birod K., et al. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem Pharmacol 2008, 76:62-69.
253. Marnett L.J. Cyclooxygenase mechanisms. Curr Opin Chem Biol 2000, 4:545-552.
254. Loll P.J., Picot D., Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995, 2:637-643.
255. Stark L.A., Din F.V., Zwacka R.M., Dunlop M.G. Aspirin-induced activation of the NF-kappaB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001, 15:1273-1275.
256. Zhou H., Liu W., Su Y., et al. NSAID sulindac and its analog bind RXRalpha and inhibit RXRalpha-dependent AKT signaling. Cancer Cell 2010, 17:560-573.
257. Bertagnolli M.M., Eagle C.J., Zauber A.G., et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-884.
258. Baron J.A., Sandler R.S., Bresalier R.S., et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006, 131:1674-1682.
259. Arber N., Eagle C.J., Spicak J., et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885-895.
260. Baron J.A., Sandler R.S., Bresalier R.S., et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008, 372:1756-1764.
261. Harris R.E. Cyclooxygenase-2 (Cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacol 2009, 17:55-67.
262. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
263. Duffield-Lillico A.J., Boyle J.O., Zhou X.K., et al. Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-Lipoxygenase pathway. Cancer Prev Res 2009, 2:322-329.
264. Wu C.Y., Wu M.S., Kuo K.N., Wang C.B., Chen Y.J., Lin J.T. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol 2010, 28:2952-2957.
265. Zrieki A., Farinotti R., Buyse M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res 2008, 25:1991-2001.
266. Sharma S., Zhu L., Yang S.C., et al. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses. J Immunol 2005, 17:813-819.
267. Tuettenberg J., Grobholz R., Korn T., Wenz F., Erber R., Vajkoczy P. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 2005, 131:31-40.
268. Milella M., Gelibter A., Di Cosimo S., et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004, 101:133-138.
269. Bundred N.J., Cramer A., Morris J., et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 2010, 16:1605-1612.
270. Antonarakis E.S., Heath E.I., Walczak J.R., et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 2009, 4986-4993.
271. Edelman M.J., Watson D., Wang X., et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008, 848-855.
272. Yan M., Myung S.-J., Fink S.P., et al. 15-hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proc Natl Acad Sci USA 2009, 106:9409-9413.
273. http://wwwclinicaltrials.gov.
274. Uddin M.J., Crews B.C., Blobaum A.L., et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res 2010, 70:3618-3627.